JPWO2020146290A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020146290A5
JPWO2020146290A5 JP2021539465A JP2021539465A JPWO2020146290A5 JP WO2020146290 A5 JPWO2020146290 A5 JP WO2020146290A5 JP 2021539465 A JP2021539465 A JP 2021539465A JP 2021539465 A JP2021539465 A JP 2021539465A JP WO2020146290 A5 JPWO2020146290 A5 JP WO2020146290A5
Authority
JP
Japan
Prior art keywords
cells
item
composition
vector
exonuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021539465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516647A (ja
JP2022516647A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012438 external-priority patent/WO2020146290A1/en
Publication of JP2022516647A publication Critical patent/JP2022516647A/ja
Publication of JP2022516647A5 publication Critical patent/JP2022516647A5/ja
Publication of JPWO2020146290A5 publication Critical patent/JPWO2020146290A5/ja
Pending legal-status Critical Current

Links

JP2021539465A 2019-01-07 2020-01-06 非毒性ｃａｓ９酵素およびその用途 Pending JP2022516647A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962789347P 2019-01-07 2019-01-07
US62/789,347 2019-01-07
US201962823477P 2019-03-25 2019-03-25
US62/823,477 2019-03-25
US201962824164P 2019-03-26 2019-03-26
US62/824,164 2019-03-26
US201962855612P 2019-05-31 2019-05-31
US62/855,612 2019-05-31
PCT/US2020/012438 WO2020146290A1 (en) 2019-01-07 2020-01-06 A non-toxic cas9 enzyme and application thereof

Publications (3)

Publication Number Publication Date
JP2022516647A JP2022516647A (ja) 2022-03-01
JP2022516647A5 JP2022516647A5 (https=) 2023-01-19
JPWO2020146290A5 true JPWO2020146290A5 (https=) 2023-01-19

Family

ID=71520905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539465A Pending JP2022516647A (ja) 2019-01-07 2020-01-06 非毒性ｃａｓ９酵素およびその用途

Country Status (8)

Country Link
US (3) US20210403922A1 (https=)
EP (1) EP3908659A4 (https=)
JP (1) JP2022516647A (https=)
CN (1) CN113811611A (https=)
AU (1) AU2020206997A1 (https=)
CA (1) CA3125009A1 (https=)
GB (2) GB2596660B (https=)
WO (1) WO2020146290A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
EP4243608A1 (en) * 2020-11-11 2023-09-20 Leibniz-Institut für Pflanzenbiochemie (IPB) Fusion protein for editing endogenous dna of a eukaryotic cell
AU2021409732A1 (en) * 2020-12-23 2023-07-20 Intellia Therapeutics, Inc. Compositions and methods for reducing hla-a in a cell
EP4317549A4 (en) * 2021-03-31 2025-03-26 Ddbio. Co, Ltd., (Shang Hai) Vector and method for screening functional antigen-binding protein
CN113481184A (zh) * 2021-08-06 2021-10-08 北京大学 融合蛋白以及其使用方法
EP4396340A4 (en) * 2021-09-01 2025-09-24 Univ Leland Stanford Junior RNA-GUIDED GENOME RECOMBINATION AT THE KILOBASE SCALE
WO2023168235A2 (en) * 2022-03-01 2023-09-07 Crisp-Hr Therapeutics, Inc. Systems and methods of gene editing
CN116286741A (zh) * 2022-03-03 2023-06-23 清华大学 5’→3’核酸外切酶在基因编辑系统中的用途和基因编辑系统及其编辑方法
EP4286401A1 (en) * 2022-06-03 2023-12-06 Technische Universität Dresden Use of an artificial protein or of a nucleic acid encoding the artificial protein for providing a functional ribonucleoprotein complex
JP2025012122A (ja) * 2023-07-12 2025-01-24 国立研究開発法人農業・食品産業技術総合研究機構 遺伝子組換えチョウ目昆虫
WO2025137069A1 (en) * 2023-12-18 2025-06-26 University Of Maryland, Baltimore Compositions and methods for enhanced genome editing using cas9 fusion proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4357457B1 (en) * 2012-10-23 2024-10-16 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
US9388430B2 (en) * 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US20150165054A1 (en) * 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2016007604A1 (en) * 2014-07-09 2016-01-14 Gen9, Inc. Compositions and methods for site-directed dna nicking and cleaving
EP3204496A1 (en) * 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
CA2963820A1 (en) * 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
US10155938B2 (en) * 2015-04-14 2018-12-18 City Of Hope Coexpression of CAS9 and TREX2 for targeted mutagenesis
GB201510296D0 (en) * 2015-06-12 2015-07-29 Univ Wageningen Thermostable CAS9 nucleases
US20170175140A1 (en) * 2015-12-16 2017-06-22 Regents Of The University Of Minnesota Methods for using a 5'-exonuclease to increase homologous recombination in eukaryotic cells
US11274288B2 (en) * 2016-02-16 2022-03-15 Emendobio Inc. Compositions and methods for promoting homology directed repair mediated gene editing
US9982267B2 (en) * 2016-10-12 2018-05-29 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
WO2018162702A1 (en) * 2017-03-10 2018-09-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nuclease fusions for enhancing genome editing by homology-directed transgene integration

Similar Documents

Publication Publication Date Title
GB2596660A (en) A non-toxic Cas9 enzyme and application thereof
US20240417706A1 (en) Systems and methods for the treatment of hemoglobinopathies
JP2025020189A (ja) 幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
WO2019067999A1 (en) IN VITRO METHOD OF ADMINISTERING MRNA USING LIPID NANOPARTICLES
JP2024050582A (ja) 新規のｏｍｎｉ－５０ｃｒｉｓｐｒヌクレアーゼ
EP4506461A1 (en) Method for repairing hba2 gene mutations by single base editing and use thereof
JPWO2020146290A5 (https=)
CA3093701A1 (en) Systems and methods for the treatment of hemoglobinopathies
WO2023019164A2 (en) High-throughput precision genome editing in human cells
WO2024125221A1 (zh) 一种碱基编辑系统及碱基编辑方法
WO2025119306A1 (zh) 优化工程化t细胞的碱基编辑系统及其应用
US20240415979A1 (en) Gene editing to treat myeloproliferative neoplasms
JPWO2021138247A5 (https=)
EP4353821A1 (en) Transposase mutant with enhanced efficiency of gene transfer
WO2020169673A1 (en) Cell penetrating transposase
US20230089784A1 (en) Methods and compositions for production of genetically modified primary cells
WO2023220649A2 (en) Effector protein compositions and methods of use thereof
CN117279671A (zh) 用于在c3安全港位点处敲入的策略
WO2024059811A2 (en) Retron directed gene editing
HK40033100A (en) In vitro method of mrna delivery using lipid nanoparticles
WO2025049792A1 (en) Compositions and methods for epigenetic regulation of tgfbr2 expression
CN118647365A (zh) 巨核细胞来源的细胞外囊泡的生物标志物
HK40105026A (zh) 用於在c3安全港位点处敲入的策略
CN119464262A (zh) 高效率、高保真腺嘌呤碱基编辑器的开发与应用
CN117940566A (zh) 用于治疗血红蛋白病的系统和方法